Remember when Hims & Hers thought it could flippantly sell knockoff weight-loss drugs and pick a fight with one of the most powerful pharmaceutical companies on earth?
A company with a market cap 55x larger than Hims and arguably some of the biggest pull in DC?
Yeah… that little adventure just ended. And it’s probably safe to assume the entire Hims executive team is doing cartwheels around the C-suite (with “All I Do Is Win” blasting somewhere in the background).
Today, Novo Nordisk announced it’s dropping its patent infringement lawsuit against Hims & Hers Health… the same lawsuit it filed earlier this year accusing the telehealth company of running what it called “mass illegal compounding.”
Translation: the Ozempic investor believed Hims was basically remixing its blockbuster weight-loss drug Wegovy and selling a discount version. And yes… an army of lawyers was absolutely warming up the flamethrowers.
But instead of dragging this thing through a multi-year courtroom cage match, the two sides quietly worked out a deal.
The terms? Hims gets to sell Novo’s actual FDA-approved drugs (including Ozempic and Wegovy) through its telehealth platform.
In exchange… Hims agreed to stop marketing compounded GLP-1 drugs to the masses. Which, I actually think is a pretty fair deal for both parties.
Novo CEO Mike Doustdar announced this morning the company has dropped the current court proceedings, though he politely added they can always reopen the case “if needed.” (Translation: behave yourself.)
Investors clearly didn’t wait around to read the settlement details. Hims shares blasted more than 50% higher the second the headline crossed the tape.
Normally in the land of Big Pharma, moves like this are reserved for things like biotech companies curing a disease… or RFK Jr. deciding not to rant about your star drug on a Joe Rogan podcast. This time around, it’s happening because a company just avoided getting obliterated in federal court.
Meanwhile, Novo’s stock rose about 1.5%, as shareholders got to avoid the awkward earnings call where management explains, “so we actually lost money this quarter because we decided to sue a telehealth startup.”
This whole fight traces back to February.
That’s when Novo sued Hims after the telehealth company announced it would sell a copycat Wegovy pill for $49… roughly $100 cheaper than Novo’s own offering through its NovoCare program.
Hims was taking advantage of a regulatory loophole that allows pharmacies to compound drugs when the branded version is in shortage. And for a while, semaglutide (the active ingredient in Ozempic and Wegovy) was hard to get.
But once Novo ramped up manufacturing and the shortages eased, the company made it very clear the loophole party was over. The U.S. Food and Drug Administration even warned it could take “decisive steps” against compounding pharmacies pushing knockoff versions of the drug. Hims quickly pulled the pill… but the lawsuit was already in motion.
Now the new arrangement basically resets the board. Hims can offer patients access to FDA-approved semaglutide treatments through its platform. But the company must stop advertising compounded GLP-1 products except in rare medical cases where customization is needed.
Which means Hims shifts from “discount Ozempic knockoff dealer” to “online distribution channel for the real thing.” And considering the insane demand for weight-loss drugs, that might not be a bad idea.
At the time of publishing this article, Stocks.News doesn’t hold positions in companies mentioned in the article.
Did you find this insightful?
Bad
Just Okay
Amazing
Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer
